<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01360749</url>
  </required_header>
  <id_info>
    <org_study_id>ISD-LAM-2010-01</org_study_id>
    <nct_id>NCT01360749</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Lambdalina (Lidocaine Cream) Versus Placebo as an Anesthetic for Laser Hair Removal</brief_title>
  <official_title>Multicentre, Double-Blind Trial to Evaluate the Efficacy and Safety of Lambdalina vs Placebo as an Anesthetic for Laser Hair Removal</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ISDIN</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ISDIN</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Double-blind, randomized, placebo-controlled trial to assess the efficacy of Lambdalina&#xD;
      (lidocaine cream) in reducing pain associated with laser hair removal in women.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">November 2011</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean change in pain intensity (Pain Visual Analogue Scale) associated to laser hair removal from baseline to the end of laser hair removal session (primary endpoint)</measure>
    <time_frame>30 minutes after treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety assessments including AEs and SAEs</measure>
    <time_frame>48 hours after treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Local Anesthesia</condition>
  <arm_group>
    <arm_group_label>Lambdalina and placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible patients will receive lambdaline (lidocaine cream 40 mg/g) in Left Lower Extremity and placebo in Right Lower Extremity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo and lambdalina</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible patients will receive placebo in Left Lower Extremity and lambdaline (lidocaine cream 40 mg/g) in Right Lower Extremity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lambdalina® (Lidocaine 4% cream)</intervention_name>
    <description>Lambdaline dose: 2 g for 10 cm2.</description>
    <arm_group_label>Lambdalina and placebo</arm_group_label>
    <arm_group_label>Placebo and lambdalina</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo dose: 2 g for 10 cm2.</description>
    <arm_group_label>Lambdalina and placebo</arm_group_label>
    <arm_group_label>Placebo and lambdalina</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Women ≥ 18 and ≤ 65 years old.&#xD;
&#xD;
          2. Laser hair removal treatment session in the legs in the area from the knee to the&#xD;
             ankle (first or second application).&#xD;
&#xD;
          3. Able of accomplishing the study's requirements.&#xD;
&#xD;
          4. Negative result in the pregnancy test.&#xD;
&#xD;
          5. Sterile or surgically sterilized women (hysterectomy, tubal ligation) or using&#xD;
             adequate contraceptive methods.&#xD;
&#xD;
          6. Written informed consent prior to inclusion in the trial.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        - General exclusion criteria:&#xD;
&#xD;
          1. Pregnant or breastfeeding.&#xD;
&#xD;
             - Current or previous medical conditions:&#xD;
&#xD;
          2. Skin type 5 or 6 or a history of photosensitivity.&#xD;
&#xD;
          3. Cardiovascular diseases such as unstable angina, or severe heart failure (New York&#xD;
             Heart Association III or IV).&#xD;
&#xD;
          4. Neuropathy or paresthesia.&#xD;
&#xD;
          5. History of hepatic failure.&#xD;
&#xD;
          6. Autoimmune diseases.&#xD;
&#xD;
          7. Allergies to peanuts and/or soy and/or any components of the formulation.&#xD;
&#xD;
          8. Use or dependence on prohibited substances.&#xD;
&#xD;
          9. Other contraindications specified in the summary of product characteristics.&#xD;
&#xD;
             - Current or previous concomitant medications:&#xD;
&#xD;
         10. Any anesthetic or analgesic treatment during 2 hours prior of study entry.&#xD;
&#xD;
         11. Concomitant treatment with antiarrhythmic drugs of class I (eg. tocainide, mexiletine)&#xD;
             or class III (eg. amiodarone, sotalol), anticoagulants, anti-platelet aggregating&#xD;
             and/or beta-blockers.&#xD;
&#xD;
         12. Active wounds or irritations in the area to be treated.&#xD;
&#xD;
         13. Topical treatment with corticosteroids or other topical agent in the area to be&#xD;
             studied.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antonio Campo Voegeli, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Clínica Dermatológica Campo De Felipe, Barcelona, Spain</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Serafín Fernández, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clínica Dermatológica Láser, Madrid, Spain</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Antonio Campo Voegeli, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clínica Dermatológica Campo De Felipe, Barcelona, Spain</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clínica Dermatológica Campo De Felipe</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clínica Dermatológica Láser</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>April 2012</verification_date>
  <study_first_submitted>May 24, 2011</study_first_submitted>
  <study_first_submitted_qc>May 25, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 26, 2011</study_first_posted>
  <last_update_submitted>April 12, 2012</last_update_submitted>
  <last_update_submitted_qc>April 12, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 13, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pain management</keyword>
  <keyword>Lidocaine</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

